## Ann H Partridge

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4656424/publications.pdf Version: 2024-02-01

		18887	17373
225	17,713	64	126
papers	citations	h-index	g-index
227	227	227	16321
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The effects of a clinicâ€based weight loss program on healthâ€related quality of life and weight maintenance in cancer survivors: A randomized controlled trial. Psycho-Oncology, 2022, 31, 326-333.	1.0	1
2	Optimal Endocrine Therapy in Premenopausal Women: A Pragmatic Approach to Unanswered Questions. JCO Oncology Practice, 2022, 18, 211-216.	1.4	10
3	Trajectories of fear of cancer recurrence in young breast cancer survivors. Cancer, 2022, 128, 335-343.	2.0	33
4	Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. British Journal of Cancer, 2022, 126, 302-309.	2.9	18
5	Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2022. 113. 117-124.	0.4	11
6	The impact of young age at diagnosis (age <40 years) on prognosis varies by breast cancer subtype: A U.S. SEER database analysis. Breast, 2022, 61, 77-83.	0.9	38
7	Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer. Clinical Cancer Research, 2022, 28, 2339-2348.	3.2	20
8	Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care. Journal of Clinical Oncology, 2022, 40, 1111-1123.	0.8	23
9	CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2022, 40, 1323-1334.	0.8	62
10	Psychosocial issues and quality of life of parenting partners of young women with breast cancer. Supportive Care in Cancer, 2022, 30, 4265-4274.	1.0	6
11	Abstract PD5-06: Safety of assisted reproductive technologies (ART) following treatment completion in young women with germline <i>BRCA</i> pathogenic variants having a pregnancy after breast cancer. Cancer Research, 2022, 82, PD5-06-PD5-06.	0.4	0
12	Abstract PD5-05: Impact of anti-HER2 therapy alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the NeoALTTO trial. Cancer Research, 2022, 82, PD5-05-PD5-05.	0.4	0
13	Abstract P2-13-42: Effect of young age at diagnosis on clinical outcomes and efficacy of anti-HER2 targeted therapy in patients with HER2-positive early breast cancer: Results from the APHINITY trial. Cancer Research, 2022, 82, P2-13-42-P2-13-42.	0.4	1
14	Abstract P4-11-20: Attitudes and factors influencing contraception use over time in premenopausal women with early breast cancer in the prospective CANTO study. Cancer Research, 2022, 82, P4-11-20-P4-11-20.	0.4	1
15	"ls it cancer or not?―A qualitative exploration of survivor concerns surrounding the diagnosis and treatment of ductal carcinoma in situ. Cancer, 2022, 128, 1676-1683.	2.0	6
16	Overcoming Obstacles in Transitions of Cancer Survivor Care. Journal of the National Cancer Institute, 2022, , .	3.0	0
17	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. Npj Breast Cancer, 2022, 8, 18.	2.3	8
18	Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis. Journal of Clinical Oncology, 2022, 40, 2148-2162.	0.8	18

#	Article	IF	CITATIONS
19	Auricular Acupuncture During Chemotherapy Infusion in Breast Cancer Patients: A Feasibility Study. , 2022, , .		Ο
20	Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy. Journal of Clinical Oncology, 2022, 40, 3190-3204.	0.8	23
21	A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer. Npj Breast Cancer, 2022, 8, 63.	2.3	18
22	Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy. Journal of the National Cancer Institute, 2022, 114, 1117-1126.	3.0	3
23	Treatment of Breast Cancer in Young Adults. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 795-806.	1.8	8
24	Understanding the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials. Breast, 2022, , .	0.9	2
25	Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials. Npj Breast Cancer, 2022, 8, .	2.3	4
26	Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer. Journal of Clinical Oncology, 2022, 40, 2408-2419.	0.8	42
27	Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D. Breast, 2022, 65, 32-40.	0.9	25
28	Body weight changes and associated predictors in a prospective cohort of young breast cancer survivors. Cancer, 2022, 128, 3158-3169.	2.0	10
29	Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea. Journal of the National Cancer Institute, 2021, 113, 1105-1108.	3.0	5
30	Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer. Breast Cancer Research and Treatment, 2021, 186, 157-165.	1.1	12
31	Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. Journal of the National Cancer Institute, 2021, 113, 443-452.	3.0	22
32	Pregnancy after breast cancer: Results from a prospective cohort of young women with breast cancer. Cancer, 2021, 127, 1021-1028.	2.0	20
33	Tumor phenotype and concordance in synchronous bilateral breast cancer in young women. Breast Cancer Research and Treatment, 2021, 186, 815-821.	1.1	6
34	Predictors of increased risk for early treatment non-adherence to oral anti-estrogen therapies in early-stage breast cancer patients. Breast Cancer Research and Treatment, 2021, 185, 53-62.	1.1	15
35	A new look at old problems: Ovarian function suppression in the real world. Cancer, 2021, 127, 1174-1176.	2.0	0
36	Prediction of Persistent Pain Severity and Impact 12 Months After Breast Surgery Using Comprehensive Preoperative Assessment of Biopsychosocial Pain Modulators. Annals of Surgical Oncology, 2021, 28, 5015-5038.	0.7	31

#	Article	IF	CITATIONS
37	Screening for Depression in Younger Breast Cancer Survivors: Outcomes From Use of the 9-item Patient Health Questionnaire. JNCI Cancer Spectrum, 2021, 5, pkab017.	1.4	8
38	Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants. Npj Breast Cancer, 2021, 7, 16.	2.3	13
39	Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic. Breast Cancer Research and Treatment, 2021, 188, 249-258.	1.1	20
40	Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance). JNCI Cancer Spectrum, 2021, 5, pkab025.	1.4	8
41	Impact of fertility concerns on endocrine therapy decisions in young breast cancer survivors. Cancer, 2021, 127, 2888-2894.	2.0	23
42	Cyclophosphamide-Free Adjuvant Chemotherapy for the Potential Prevention of Premature Ovarian Insufficiency and Infertility in Young Women With Breast Cancer. Journal of the National Cancer Institute, 2021, 113, 1274-1276.	3.0	3
43	Assessment of Ovarian Function in PhaseÂIII (Neo)Adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation. Journal of the National Cancer Institute, 2021, , .	3.0	11
44	The impact of fertility preservation on the timing of breast cancer treatment, recurrence, and survival. Cancer, 2021, 127, 3872-3880.	2.0	13
45	The definition of pregnancy-associated breast cancer is outdated and should no longer be used. Lancet Oncology, The, 2021, 22, 753-754.	5.1	57
46	Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRCO33: ATEMPT Trial). Breast Cancer Research and Treatment, 2021, 189, 103-110.	1.1	19
47	Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. Lancet Oncology, The, 2021, 22, e303-e313.	5.1	116
48	Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis. Journal of Clinical Oncology, 2021, 39, 3293-3305.	0.8	70
49	Treatment-related amenorrhea in a modern, prospective cohort study of young women with breast cancer. Npj Breast Cancer, 2021, 7, 99.	2.3	11
50	Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. Journal of Clinical Oncology, 2021, 39, 2375-2385.	0.8	76
51	Targeting Depressive Symptoms in Younger Breast Cancer Survivors: The Pathways to Wellness Randomized Controlled Trial of Mindfulness Meditation and Survivorship Education. Journal of Clinical Oncology, 2021, 39, 3473-3484.	0.8	29
52	Statins to mitigate cardiotoxicity in cancer patients treated with anthracyclines and/or trastuzumab: a systematic review and meta-analysis. Cancer Causes and Control, 2021, 32, 1395-1405.	0.8	22
53	Young, Empowered and Strong: A Web-Based Education and Supportive Care Intervention for Young Women With Breast Cancer Across the Care Continuum. JCO Clinical Cancer Informatics, 2021, 5, 933-943.	1.0	9
54	Association of Local Therapy With Quality-of-Life Outcomes in Young Women With Breast Cancer. JAMA Surgery, 2021, 156, e213758.	2.2	18

#	Article	IF	CITATIONS
55	Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. Nature Communications, 2021, 12, 5563.	5.8	19
56	Reply to M. Tanaka et al. Journal of Clinical Oncology, 2021, 39, JCO.21.01967.	0.8	0
57	Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. Breast, 2021, 59, 327-338.	0.9	31
58	Cancer Survivorship in Latin America: Current Status and Opportunities. JCO Global Oncology, 2021, 7, 1472-1479.	0.8	5
59	Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1Â+ tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. Future Oncology, 2021, 17, 4665-4676.	1.1	8
60	Optimizing Decision Making for Ductal Carcinoma in Situ: Facts Over Fear. Journal of the National Cancer Institute, 2021, 113, 511-512.	3.0	0
61	Comparison of Equations To Estimate Glomerular Filtration Rate and Their Impact on Frequency of Cisplatin-associated Acute Kidney Injury. Kidney360, 2021, 2, 205-214.	0.9	4
62	Aggressive Subsets of Metastatic Triple Negative Breast Cancer. Clinical Breast Cancer, 2020, 20, e20-e26.	1.1	5
63	Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors: A Randomized Controlled Pilot Trial. Oncologist, 2020, 25, 310-318.	1.9	92
64	Interventions to Enhance Adherence to Oral Antineoplastic Agents: A Scoping Review. Journal of the National Cancer Institute, 2020, 112, 443-465.	3.0	35
65	Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer. Journal of Clinical Oncology, 2020, 38, 725-733.	0.8	46
66	Prospective evaluation of the impact of stress, anxiety, and depression on household income among young women with early breast cancer from the Young and Strong trial. BMC Public Health, 2020, 20, 1514.	1.2	6
67	Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. Journal of Clinical Oncology, 2020, 38, 4184-4193.	0.8	74
68	Partners of young breast cancer survivors: a cross-sectional evaluation of psychosocial concerns, coping, and mental health. Journal of Psychosocial Oncology, 2020, 38, 670-686.	0.6	13
69	Effect of Sustained Smoking Cessation Counseling and Provision of Medication vs Shorter-term Counseling and Medication Advice on Smoking Abstinence in Patients Recently Diagnosed With Cancer. JAMA - Journal of the American Medical Association, 2020, 324, 1406.	3.8	61
70	Pregnancy After Breast Cancer in Patients With Germline <i>BRCA</i> Mutations. Journal of Clinical Oncology, 2020, 38, 3012-3023.	0.8	69
71	Body weight and return to work among survivors of early-stage breast cancer. ESMO Open, 2020, 5, e000908.	2.0	9
72	The utility of magnetic resonance imaging in earlyâ€stage breast cancer survivors—An institutional experience and literature review. Breast Journal, 2020, 26, 1673-1679.	0.4	1

#	Article	IF	CITATIONS
73	Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor–Positive, <i>ERBB2</i> -Negative Metastatic Breast Cancer. JAMA Oncology, 2020, 6, 1598.	3.4	84
74	Estimation of historical control rate for a single arm de-escalation study – Application to the POSITIVE trial. Breast, 2020, 53, 1-7.	0.9	13
75	Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk. Journal of Clinical Oncology, 2020, 38, 2762-2772.	0.8	80
76	Posttraumatic stress in breast cancer survivors diagnosed at a young age. Psycho-Oncology, 2020, 29, 1312-1320.	1.0	15
77	The Patient's Voice: Adherence, Symptoms, and Distress Related to Adjuvant Endocrine Therapy After Breast Cancer. International Journal of Behavioral Medicine, 2020, 27, 687-697.	0.8	19
78	Association of post-diagnosis cardiorespiratory fitness with cause-specific mortality in cancer. European Heart Journal Quality of Care & Clinical Outcomes, 2020, 6, 315-322.	1.8	43
79	Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. Clinical Cancer Research, 2020, 26, 2556-2564.	3.2	109
80	Fertility Counseling and Preservation in Breast Cancer. Current Breast Cancer Reports, 2020, 12, 1-12.	0.5	0
81	Changes in weight, physical and psychosocial patient-reported outcomes among obese women receiving treatment for early-stage breast cancer: A nationwide clinical study. Breast, 2020, 52, 23-32.	0.9	15
82	Genetic predictors of chemotherapy-related amenorrhea inÂwomen with breast cancer. Fertility and Sterility, 2019, 112, 731-739.e1.	0.5	10
83	Contemporary management of breast cancer during pregnancy and subsequent lactation in a multicenter cohort of young women with breast cancer. Breast Journal, 2019, 25, 1104-1110.	0.4	10
84	Impact of Timing on Measurement of Decision Quality and Shared Decision Making: Longitudinal Cohort Study of Breast Cancer Patients. Medical Decision Making, 2019, 39, 642-650.	1.2	10
85	A randomized study to improve care for young women with breast cancer at community and academic medical oncology practices in the United States: The Young and Strong study. Cancer, 2019, 125, 1799-1806.	2.0	12
86	Reproductive Health Issues for Young Women with Breast Cancer: Emerging Strategies for Difficult Situations. Annals of Surgical Oncology, 2019, 26, 1170-1172.	0.7	1
87	Lasting effects of cancer and its treatment on employment and finances in adolescent and young adult cancer survivors. Cancer, 2019, 125, 1908-1917.	2.0	66
88	Evaluation of significant genome-wide association studies risk — SNPs in young breast cancer patients. PLoS ONE, 2019, 14, e0216997.	1.1	4
89	Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer. Cancer, 2019, 125, 3266-3274.	2.0	37
90	Sexual Function among Women in Midlife: Findings from the Nurses' Health Study II. Women's Health Issues, 2019, 29, 291-298.	0.9	7

#	Article	IF	CITATIONS
91	Local–regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). Breast Cancer Research and Treatment, 2019, 176, 303-310.	1.1	30
92	Cancer Treatment-Related Infertility: A Critical Review of the Evidence. JNCI Cancer Spectrum, 2019, 3, pkz008.	1.4	75
93	Identifying distinct trajectories of change in young breast cancer survivors' sexual functioning. Psycho-Oncology, 2019, 28, 1033-1040.	1.0	15
94	Fatigue and physical activity in cancer survivors: A crossâ€sectional populationâ€based study. Cancer Medicine, 2019, 8, 2535-2544.	1.3	26
95	Variability in diagnostic threshold for comedo necrosis among breast pathologists: implications for patient eligibility for active surveillance trials of ductal carcinoma in situ. Modern Pathology, 2019, 32, 1257-1262.	2.9	27
96	Factors Affecting Surgical Decisions in Newly Diagnosed Young Women with Early-Stage Breast Cancer. Journal of Adolescent and Young Adult Oncology, 2019, 8, 463-468.	0.7	9
97	The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). BMJ Open, 2019, 9, e026797.	0.8	182
98	Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer. Journal of Clinical Oncology, 2019, 37, 1868-1875.	0.8	229
99	Clinical Benefit in the Treatment of Patients with Early Breast Cancer. Breast, 2019, 48, S115-S118.	0.9	1
100	Amenorrhea after lung cancer treatment. Menopause, 2019, 26, 306-310.	0.8	5
101	Case ontrol study of heart rate abnormalities across the breast cancer survivorship continuum. Cancer Medicine, 2019, 8, 447-454.	1.3	4
102	Preoperative Psychosocial and Psychophysical Phenotypes as Predictors of Acute Pain Outcomes After Breast Surgery. Journal of Pain, 2019, 20, 540-556.	0.7	51
103	Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in youngBRCA-mutated breast cancer patients. Reproductive BioMedicine Online, 2019, 38, 835-844.	1.1	29
104	Pregnancy-Associated Cancer: A U.S. Population-Based Study. Journal of Women's Health, 2019, 28, 250-257.	1.5	87
105	Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: From biological evidence to clinical application. Cancer Treatment Reviews, 2019, 72, 65-77.	3.4	83
106	Anxiety and Depression in Young Women With Metastatic Breast Cancer: A Cross-Sectional Study. Psychosomatics, 2018, 59, 251-258.	2.5	105
107	Exogenous reproductive hormone use in breast cancer survivors and previvors. Nature Reviews Clinical Oncology, 2018, 15, 249-261.	12.5	19
108	Randomized trial of a clinic-based weight loss intervention in cancer survivors. Journal of Cancer Survivorship, 2018, 12, 186-195.	1.5	15

#	Article	IF	CITATIONS
109	Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology, 2018, 36, 1994-2001.	0.8	979
110	Development and Validation of a Risk Prediction Model for Acute Kidney Injury After the First Course of Cisplatin. Journal of Clinical Oncology, 2018, 36, 682-688.	0.8	90
111	Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2018, 36, 543-553.	0.8	162
112	Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient–Level Data. Journal of Clinical Oncology, 2018, 36, 1981-1990.	0.8	268
113	Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. Journal of Clinical Oncology, 2018, 36, 2433-2443.	0.8	131
114	Pregnancy after cancer: Timing is everything. Cancer, 2018, 124, 4290-4291.	2.0	1
115	Epidemiology, Biology, Treatment, and Prevention of Ductal Carcinoma In Situ (DCIS). JNCI Cancer Spectrum, 2018, 2, pky063.	1.4	17
116	The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. Breast, 2018, 42, 41-49.	0.9	75
117	Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health. Menopause, 2018, 25, 596-608.	0.8	143
118	Psychosocial needs of young breast cancer survivors in Mexico City, Mexico. PLoS ONE, 2018, 13, e0197931.	1.1	39
119	Is there a role for older-patient-specific cancer clinical trials? A pooled analysis of 2277 older patients in adjuvant breast cancer trials (Alliance A151715) Journal of Clinical Oncology, 2018, 36, 10034-10034.	0.8	1
120	Symptom burden and employment status in breast cancer (BC) survivors Journal of Clinical Oncology, 2018, 36, 10073-10073.	0.8	3
121	Mortality following breast cancer in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study Journal of Clinical Oncology, 2018, 36, 10511-10511.	0.8	1
122	Comparison of operative to monitoring and endocrine therapy for low-risk DCIS (COMET study) Journal of Clinical Oncology, 2018, 36, TPS599-TPS599.	0.8	4
123	Fertility concerns among breast cancer patients in Mexico. Breast, 2017, 33, 71-75.	0.9	21
124	Oncofertility: Fertile Ground for Conflict Between Patient Autonomy and Medical Values. Oncologist, 2017, 22, 860-863.	1.9	11
125	Surveillance Mammography in Older Patients With Breast Cancer—Can We Ever Stop?. JAMA Oncology, 2017, 3, 402.	3.4	27
126	Emerging Data and Current Challenges for Young, Old, Obese, or Male Patients with Breast Cancer. Clinical Cancer Research, 2017, 23, 2647-2654.	3.2	25

#	Article	IF	CITATIONS
127	Unmet Needs in Clinical Research in Breast Cancer: Where Do We Need to Go?. Clinical Cancer Research, 2017, 23, 2611-2616.	3.2	18
128	Survival benefit needed to undergo chemotherapy: Patient and physician preferences. Cancer, 2017, 123, 2821-2828.	2.0	16
129	A Standard Set of Value-Based Patient-Centered Outcomes for Breast Cancer. JAMA Oncology, 2017, 3, 677.	3.4	167
130	Looking back, moving forward: the evolution of cancer survivorship care. Lancet Oncology, The, 2017, 18, 18-19.	5.1	13
131	Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast Cancers. Cancer Discovery, 2017, 7, 202-217.	7.7	57
132	The Rodent Liver Undergoes Weaning-Induced Involution and Supports Breast Cancer Metastasis. Cancer Discovery, 2017, 7, 177-187.	7.7	42
133	ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). Breast, 2017, 35, 203-217.	0.9	203
134	Surgical Upstaging Rates for Vacuum Assisted Biopsy Proven DCIS: Implications for Active Surveillance Trials. Annals of Surgical Oncology, 2017, 24, 3534-3540.	0.7	76
135	Treatment of Breast Cancer During Pregnancy. Current Breast Cancer Reports, 2017, 9, 195-201.	0.5	0
136	Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy?. Breast Cancer Research and Treatment, 2017, 165, 545-553.	1.1	2
137	Oncology Physicians' Perspectives on Practices and Barriers to Fertility Preservation and the Feasibility of a Prospective Study of Pregnancy After Breast Cancer. Journal of Adolescent and Young Adult Oncology, 2017, 6, 429-434.	0.7	26
138	Risk communication and decision-making in the prevention of invasive breast cancer. Breast, 2017, 34, S55-S57.	0.9	3
139	Effect of the LIVESTRONG at the YMCA exercise program on physical activity, fitness, quality of life, and fatigue in cancer survivors. Cancer, 2017, 123, 1249-1258.	2.0	87
140	Feasibility and Acceptability of a Web Site to Promote Survivorship Care in Survivors of Hodgkin Disease. JCO Clinical Cancer Informatics, 2017, 1, 1-10.	1.0	3
141	Reply to L. Del Mastro and A. Prat. Journal of Clinical Oncology, 2017, 35, 1139-1139.	0.8	Ο
142	Endocrine therapy non-persistence in young women with early-stage breast cancer Journal of Clinical Oncology, 2017, 35, 531-531.	0.8	1
143	Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer. Breast Cancer Research and Treatment, 2016, 158, 243-251.	1.1	40
144	Randomized trial of a physical activity intervention in women with metastatic breast cancer. Cancer, 2016, 122, 1169-1177.	2.0	87

#	Article	IF	CITATIONS
145	Fertility Preservation in Patients With Breast Cancer: Necessity, Methods, and Safety. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 355-363.	2.3	32
146	Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) –Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline. Journal of Clinical Oncology, 2016, 34, 2416-2427.	0.8	112
147	Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care. Breast Cancer Research and Treatment, 2016, 160, 393-410.	1.1	58
148	Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival. Journal of Clinical Oncology, 2016, 34, 3308-3314.	0.8	297
149	Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426). Breast Cancer Research and Treatment, 2016, 159, 109-118.	1.1	47
150	Randomized phase 2 trial of a coordinated breast cancer followâ€up care program. Cancer, 2016, 122, 3546-3554.	2.0	12
151	Evaluating the Utility of Baseline Cardiac Function Screening in Early-Stage Breast Cancer Treatment. Oncologist, 2016, 21, 666-670.	1.9	17
152	Higher Stage of Disease Is Associated With Bilateral Mastectomy Among Patients With Breast Cancer: A Population-Based Survey. Clinical Breast Cancer, 2016, 16, 105-112.	1.1	13
153	<i>BRCA1</i> and <i>BRCA2</i> Mutation Testing in Young Women With Breast Cancer. JAMA Oncology, 2016, 2, 730.	3.4	105
154	Cancer and fertility preservation: international recommendations from an expert meeting. BMC Medicine, 2016, 14, 1.	2.3	521
155	Second international consensus guidelines for breast cancer in young women (BCY2). Breast, 2016, 26, 87-99.	0.9	142
156	Perceptions, Attributions, and Emotions Toward Endocrine Therapy in Young Women with Breast Cancer. Journal of Adolescent and Young Adult Oncology, 2016, 5, 16-23.	0.7	26
157	A pilot videoconference group stress management program in cancer survivors: lessons learned. Rural and Remote Health, 2016, 16, 3863.	0.4	6
158	Chemotherapy in Premenopausal Breast Cancer Patients. Breast Care, 2015, 10, 307-310.	0.8	11
159	Partner support and anxiety in young women with breast cancer. Psycho-Oncology, 2015, 24, 1679-1685.	1.0	65
160	Challenges to Standardizing the Care for Adult Cancer Survivors: Highlighting ASCO's Fatigue and Anxiety and Depression Guidelines. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 188-194.	1.8	6
161	Self-reported adherence to oral cancer therapy: relationships with symptom distress, depression, and personal characteristics. Patient Preference and Adherence, 2015, 9, 1587.	0.8	52
162	Chemo- and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary. Journal of Oncology Practice, 2015, 11, 42-43.	2.5	4

#	Article	IF	CITATIONS
163	Symptoms and Symptom Attribution Among Women on Endocrine Therapy for Breast Cancer. Oncologist, 2015, 20, 598-604.	1.9	40
164	New Insights Into Nonadherence With Adjuvant Endocrine Therapy Among Young Women With Breast Cancer. Journal of the National Cancer Institute, 2015, 107, djv245.	3.0	21
165	Management of breast cancer in very young women. Breast, 2015, 24, S154-S158.	0.9	79
166	Prevention of Premature Menopause and Preservation of Fertility in Young Cancer Survivors. JAMA - Journal of the American Medical Association, 2015, 314, 2625.	3.8	4
167	Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer. New England Journal of Medicine, 2015, 372, 134-141.	13.9	598
168	Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy. New England Journal of Medicine, 2015, 372, 923-932.	13.9	452
169	Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women. Oncologist, 2015, 20, 713-718.	1.9	19
170	Breast Cancer in Young Women. JAMA Oncology, 2015, 1, 877.	3.4	54
171	Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?. Breast, 2015, 24, 201-207.	0.9	97
172	Study protocol for Young & Strong: a cluster randomized design to increase attention to unique issues faced by young women with newly diagnosed breast cancer. BMC Public Health, 2015, 15, 37.	1.2	41
173	Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors. Journal of Clinical Oncology, 2015, 33, 2254-2261.	0.8	232
174	Chemotherapy-related amenorrhea after adjuvant paclitaxel–trastuzumab (APT trial). Breast Cancer Research and Treatment, 2015, 151, 589-596.	1.1	65
175	Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer. Annals of Surgical Oncology, 2015, 22, 3809-3815.	0.7	81
176	Developing a Service Model That Integrates Palliative Care Throughout Cancer Care: The Time Is Now. Journal of Clinical Oncology, 2014, 32, 3330-3336.	0.8	80
177	Desired Elements and Timing of Cancer Survivorship Care: One Approach May Not Fit All. Journal of Oncology Practice, 2014, 10, e293-e298.	2.5	35
178	Estimates of Young Breast Cancer Survivors at Risk for Infertility in the U.S Oncologist, 2014, 19, 814-822.	1.9	46
179	Treatmentâ€related amenorrhea and sexual functioning in young breast cancer survivors. Cancer, 2014, 120, 2264-2271.	2.0	93
180	ABCDE Steps to Prevent Heart Disease in Breast Cancer Survivors. Circulation, 2014, 130, e157-9.	1.6	32

#	Article	lF	CITATIONS
181	First international consensus guidelines for breast cancer in young women (BCY1). Breast, 2014, 23, 209-220.	0.9	135
182	Biology of breast cancer in young women. Breast Cancer Research, 2014, 16, 427.	2.2	296
183	Prospective Study of Fertility Concerns and Preservation Strategies in Young Women With Breast Cancer. Journal of Clinical Oncology, 2014, 32, 1151-1156.	0.8	313
184	Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2014, 32, 3307-3329.	0.8	210
185	Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry. Breast Cancer Research and Treatment, 2014, 145, 525-534.	1.1	91
186	Screening, Assessment, and Care of Anxiety and Depressive Symptoms in Adults With Cancer: An American Society of Clinical Oncology Guideline Adaptation. Journal of Clinical Oncology, 2014, 32, 1605-1619.	0.8	558
187	Extended Therapy With Letrozole and Ovarian Suppression in Premenopausal Patients With Breast Cancer After Tamoxifen. Clinical Breast Cancer, 2014, 14, 413-416.	1.1	16
188	Informational needs and the quality of life of patients in their first year after metastatic breast cancer diagnosis. Journal of Community and Supportive Oncology, 2014, 12, 347-354.	0.1	20
189	Contralateral prophylactic mastectomy in women with breast cancer: trends, predictors, and areas for future research. Breast Cancer Research and Treatment, 2013, 140, 447-452.	1.1	46
190	Effect of Age on Breast Cancer Outcomes in Women With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From a Herceptin Adjuvant Trial. Journal of Clinical Oncology, 2013, 31, 2692-2698.	0.8	99
191	Implementing a breast cancer registry and treatment plan/summary program in clinical practice: A pilot program. Cancer, 2013, 119, 158-163.	2.0	10
192	Supportive care after curative treatment for breast cancer (survivorship care): Resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. Breast, 2013, 22, 606-615.	0.9	87
193	Risk-Based Health Care, the Cancer Survivor, the Oncologist, and the Primary Care Physician. Seminars in Oncology, 2013, 40, 804-812.	0.8	125
194	Cancer Survivorship and the Young Breast Cancer Patient: Addressing the Important Issues. Oncologist, 2013, 18, e19-e20.	1.9	25
195	Body image in recently diagnosed young women with early breast cancer. Psycho-Oncology, 2013, 22, 1849-1855.	1.0	123
196	Evaluating the effect of esthetically enhanced materials compared to standard materials on clinician response rates to a mailed survey. International Journal of Social Research Methodology: Theory and Practice, 2013, 16, 301-306.	2.3	4
197	Young Women with Breast Cancer: A Focus Group Study of Unmet Needs. Journal of Adolescent and Young Adult Oncology, 2013, 2, 153-160.	0.7	59
198	Model Program to Improve Care for a Unique Cancer Population: Young Women With Breast Cancer. Journal of Oncology Practice, 2012, 8, e105-e110.	2.5	46

#	Article	IF	CITATIONS
199	The Effect of Age on Delay in Diagnosis and Stage of Breast Cancer. Oncologist, 2012, 17, 775-782.	1.9	97
200	Challenges in ductal carcinoma in situ risk communication and decisionâ€making. Ca-A Cancer Journal for Clinicians, 2012, 62, 203-210.	157.7	27
201	The Unique Reproductive Concerns of Young Women with Breast Cancer. Advances in Experimental Medicine and Biology, 2012, 732, 77-87.	0.8	17
202	Menopausal symptoms and fertility concerns in premenopausal breast cancer survivors. Menopause, 2011, 18, 105-108.	0.8	60
203	Pregnancy after breast cancer: if you wish, ma'am. Breast Cancer Research and Treatment, 2011, 129, 309-317.	1.1	81
204	The effects of paclitaxel, dose density, and trastuzumab on treatmentâ€related amenorrhea in premenopausal women with breast cancer. Cancer, 2010, 116, 791-798.	2.0	131
205	Adherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104. Journal of Clinical Oncology, 2010, 28, 2418-2422.	0.8	116
206	Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertility and Sterility, 2010, 94, 638-644.	0.5	173
207	Patient adherence and persistence with oral anticancer treatment. Ca-A Cancer Journal for Clinicians, 2009, 59, 56-66.	157.7	496
208	The impact of sharing results of a randomized breast cancer clinical trial with study participants. Breast Cancer Research and Treatment, 2009, 115, 123-129.	1.1	23
209	Perceptions and Management Approaches of Physicians Who Care for Women with Ductal Carcinoma In Situ. Clinical Breast Cancer, 2008, 8, 275-280.	1.1	35
210	Fertility and Menopausal Outcomes in Young Breast Cancer Survivors. Clinical Breast Cancer, 2008, 8, 65-69.	1.1	69
211	Adherence to Initial Adjuvant Anastrozole Therapy Among Women With Early-Stage Breast Cancer. Journal of Clinical Oncology, 2008, 26, 556-562.	0.8	432
212	Risk Perceptions and Psychosocial Outcomes of Women With Ductal Carcinoma In Situ: Longitudinal Results From a Cohort Study. Journal of the National Cancer Institute, 2008, 100, 243-251.	3.0	153
213	Age of menopause among women who remain premenopausal following treatment for early breast cancer: Long-term results from International Breast Cancer Study Group Trials V and VI. European Journal of Cancer, 2007, 43, 1646-1653.	1.3	130
214	Fertility and adjuvant treatment in young women with breast cancer. Breast, 2007, 16, 175-181.	0.9	84
215	American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer Patients. Journal of Clinical Oncology, 2006, 24, 2917-2931.	0.8	1,800
216	Offering participants results of a clinical trial: sharing results of a negative study. Lancet, The, 2005, 365, 963-964.	6.3	92

#	Article	IF	CITATIONS
217	Pregnancy and breast cancer: epidemiology, treatment, and safety issues. Oncology, 2005, 19, 693-7; discussion 697-700.	0.4	4
218	Web-Based Survey of Fertility Issues in Young Women With Breast Cancer. Journal of Clinical Oncology, 2004, 22, 4174-4183.	0.8	675
219	Oncology Physician and Nurse Practices and Attitudes Regarding Offering Clinical Trial Results To Study Participants. Journal of the National Cancer Institute, 2004, 96, 629-632.	3.0	61
220	Nonadherence to Adjuvant Tamoxifen Therapy in Women With Primary Breast Cancer. Journal of Clinical Oncology, 2003, 21, 602-606.	0.8	593
221	Adherence to Therapy With Oral Antineoplastic Agents. Journal of the National Cancer Institute, 2002, 94, 652-661.	3.0	477
222	Informing Clinical Trial Participants About Study Results. JAMA - Journal of the American Medical Association, 2002, 288, 363.	3.8	140
223	Nonmalignant Diagnoses in Patients. Journal of Clinical Oncology, 2000, 18, 2635-2636.	0.8	4
224	Nonmalignant Diagnoses in Patients. Journal of Clinical Oncology, 2000, 18, 2636-2637.	0.8	7
225	The prevalence and predictors of adjuvant chemotherapy use among patients treated with neoadjuvant endocrine therapy. Breast Cancer Research and Treatment, 0, , .	1.1	1